BioFire

The contract anticipates the procurement of a BioFire analyzer or equivalent FDA-approved PCR CLIA-waived system capable of detecting a comprehensive panel of respiratory pathogens from a single specimen, including adenovirus, SARS-CoV-2, seasonal coronaviruses, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, influenza A/H3 and A/H1-2009 subtypes, respiratory syncytial virus, Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae. The system must also include purchase of test panels and necessary equipment to support operational deployment across Indian Health Service facilities. The technology is intended for rapid, multiplex diagnostics with high sensitivity and specificity to improve clinical decision-making in resource-limited settings. This procurement is forecasted under NAICS code 423450 for medical and democratic equipment and supplies merchant wholesalers, and is managed by the Indian Health Service with Benjamin Olson serving as the program point of contact and Maryann Yocham as the contracting officer. The contract is not yet open for bidding but is scheduled for potential release in 2026, providing vendors time to prepare responsive proposals. The equipment will be deployed to support public health response and diagnostic capacity within tribal and Native American communities under the jurisdiction of the Indian Health Service, emphasizing timely and accurate detection of respiratory infections to reduce morbidity and support outbreak containment.